APA (7th ed.) Citation

Thomas, S., Wermke, M., Vučinić, V., Wagner-Drouet, E., Mackensen, A., Zeiser, R., . . . Schendel, D. J. (2025). First-in-human study of MDG1011, a TCR-T therapy directed against HLA-A*02: 01-Restricted PRAME antigen for high-risk myeloid and lymphoid neoplasms. Cancers, 17(18), . https://doi.org/10.3390/cancers17182968

Chicago Style (17th ed.) Citation

Thomas, Simone, et al. "First-in-human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02: 01-Restricted PRAME Antigen for High-risk Myeloid and Lymphoid Neoplasms." Cancers 17, no. 18 (2025). https://doi.org/10.3390/cancers17182968.

MLA (9th ed.) Citation

Thomas, Simone, et al. "First-in-human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02: 01-Restricted PRAME Antigen for High-risk Myeloid and Lymphoid Neoplasms." Cancers, vol. 17, no. 18, 2025, https://doi.org/10.3390/cancers17182968.